🔥 Thursday 15 May 2025 Thu, 15 May 2025

GrainCorp Limited reported a strong first half with revenue up 21% to $4.09 billion and net profit rising 17% to $58.1 million, prompting an increased dividend and share buy-back program.

Tamboran Resources has completed a major stimulation campaign on its Shenandoah South well and raised US$55.4 million to fund further drilling, positioning itself to meet critical gas supply commitments in Australia’s Northern Territory.

Kincora Copper Limited reports a strategic pivot to a project generator model, unlocking over A$110 million in partner funding and advancing multiple copper-gold exploration projects across Australia and Mongolia.

Xero Limited reported a robust FY25 with 23% revenue growth and a 22% rise in adjusted EBITDA, underpinned by subscriber and ARPU gains across key markets. The company is doubling down on AI integration and disciplined capital allocation to sustain momentum.

Xero Limited has reported a robust FY25 with 23% revenue growth and a Rule of 40 score exceeding 44%, underscoring its balanced approach to growth and profitability.

Xero Limited reported a robust FY25 with 23% revenue growth to NZ$2.1 billion and a 30% rise in net profit, driven by strategic investments in AI and product innovation. Leadership changes and a CEO pay review underscore the company’s global ambitions.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.

Minbos Resources advances its Cabinda Phosphate Project with strong sales interest and a $36 million financing package, positioning itself as a key player in Angola's agricultural transformation.

PVW Resources reports promising assay results from its Capão Bonito rare earth project and expands exploration efforts across Brazil, bolstered by new metallurgical expertise.

WA1 Resources has reported outstanding assay results from its Luni niobium deposit, highlighting some of the highest grades to date and setting the stage for an updated Mineral Resource estimate in June.

FireFly Metals’ maiden drilling at the Rambler Main Mine within the Green Bay Project has uncovered high-grade copper-gold-zinc mineralisation extending well beyond historical limits, hinting at a potential new flagship deposit akin to the nearby Ming Mine.

Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.

Euro Manganese Inc. reported a net loss of CAD 9.174 million for the half-year ending March 31, 2025, while making significant progress on its Chvaletice Manganese Project, including securing key permits and strategic status under EU and Czech frameworks. The company’s development hinges on completing a crucial private placement and share purchase plan to sustain operations.

Northern Star Resources reports a substantial 9.4 million ounce increase in group Mineral Resources to 70.7 million ounces and a 1.4 million ounce rise in Ore Reserves to 22.3 million ounces as of March 2025, excluding the newly acquired Hemi Project.

Bayan Mining and Minerals Limited has confirmed promising high-grade Carlin-style gold mineralisation at its 100% owned Bayan Springs Projects in Nevada, with rock chip assays up to 4.56 g/t Au and strong geochemical signatures.

Brightstar Resources has kicked off its second ore processing campaign under a key agreement with Genesis Minerals, while development at its Fish underground mine remains on track for first ore in June. The company is poised for growth with a near-complete feasibility study and increased drilling activity.

Blue Star Helium reports robust natural flow rates from its Jackson 2 well at the Galactica project, with helium concentrations nearing 78%, signaling strong reservoir potential in Colorado.

Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows a 60.8% response rate in first-line non-small cell lung cancer, outperforming historical benchmarks especially in patients with low PD-L1 expression.